Saniona AB (STO:SANION) announced on Thursday that the members of its nomination committee, for the 2018 Annual General Meeting, are Søren Skjærbæk, partner at Saxo lawyers, Vejle, Denmark, appointed by Jørgen Drejer; John Haurum, CEO of F-star Biotechnology Limited, Cambridge, UK, appointed by Thomas Feldthus and Claus Bræstrup, chairman of Saniona's board of directors.
Reportedly, the Annual General Meeting on 23 May 2017 had resolved that a nomination committee shall be appointed comprising of three members, which should be representatives of the two largest shareholders as of 30 September 2017, together with the chairman of the board of directors.
On 30 September 2017, the two largest shareholders, which desired to appoint a representative to the nomination committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative.
According to the company, this nomination committee shall prepare and submit proposals to the 2018 Annual General Meeting regarding election of the chairman at the AGM; election of the chairman and other members of the board; remuneration for the chairman and for each of the other members of the board and, if applicable, remuneration for committee work; election of the auditor and the auditor's remuneration and principles for appointing the nomination committee.
Saniona's Annual General Meeting will be held on 24 May 2018 in Malmö.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference